Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

DOI: 10.5306/wjco.v10.i2.52

Keywords: Angiogenesis inhibition, Second-line chemotherapy, Colorectal cancer, Bevacizumab, Aflibercept, Ramucirumab

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text